RAF1 and melanoma: Ganetespib destabilized MAPK signaling in melanoma cells by diminution of HSP90 client proteins including CRAF and BRAFV600E leading to attenuation of MEK1/2 and ERK1/2 activity in a concentration-dependent manner, while not affecting BRAF protein level in wild-type BRAF melanoma cells and melanocytes [121, 122].